CEACAM5 and neoplasm: The tumor marker levels decreased during chemotherapy, especially when FOLFOXIRI with bevacizumab was administered (carcinoembryonic antigen decreased from 136.3 to 1.6 ng/mL; carbohydrate antigen 19–9 decreased from 391.3 to 5.8 IU/mL; Figure 4).